In yesterday’s Wall Street session, Gossamer Bio Inc (NASDAQ:GOSS) shares traded at $0.49, up 2.45% from the previous session.
11 analysts cover Gossamer Bio Inc (NASDAQ:GOSS), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $1.25, we find $4.00. Given the previous closing price of $0.48, this indicates a potential upside of 733.33 percent. GOSS stock price is now -42.34% away from the 50-day moving average and -63.80% away from the 200-day moving average. The market capitalization of the company currently stands at $110.41M.
The stock has received a hold rating from 4 analysts and a buy rating from 6. Brokers who have rated the stock have averaged $5.31 as their price target over the next twelve months.
With the price target reduced from $8 to $1.25, UBS Downgraded its rating from Buy to Neutral for Gossamer Bio Inc (NASDAQ: GOSS).
In other news, Aranda Richard, Chief Medical Officer sold 1,814 shares of the company’s stock on Jun 22. The stock was sold for $2,340 at an average price of $1.29. Upon completion of the transaction, the Chief Medical Officer now directly owns 197,574 shares in the company, valued at $96811.26. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 04, COO/CFO Giraudo Bryan bought 55,000 shares of the business’s stock. A total of $56,094 was incurred on buying the stock at an average price of $1.02. This leaves the insider owning 125,990 shares of the company worth $61735.1. Insiders disposed of 22,970 shares of company stock worth roughly $11255.3 over the past 1 year. A total of 16.27% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GOSS stock. A new stake in Gossamer Bio Inc shares was purchased by OPALEYE MANAGEMENT INC. during the first quarter worth $1,651,000. APIS CAPITAL ADVISORS, LLC invested $88,000 in shares of GOSS during the first quarter. In the first quarter, VERITION FUND MANAGEMENT LLC acquired a new stake in Gossamer Bio Inc valued at approximately $83,000. VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC acquired a new stake in GOSS for approximately $22,000. OLD MISSION CAPITAL, LLC purchased a new stake in GOSS valued at around $13,000 in the second quarter. In total, there are 147 active investors with 24.76% ownership of the company’s stock.
On Wednesday morning Gossamer Bio Inc (NASDAQ: GOSS) stock kicked off with the opening price of $0.4875. During the past 12 months, Gossamer Bio Inc has had a low of $0.45 and a high of $12.48. The fifty day moving average price for GOSS is $0.8369 and a two-hundred day moving average price translates $1.3454 for the stock.
The latest earnings results from Gossamer Bio Inc (NASDAQ: GOSS) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.45, beating analysts’ expectations of -$0.49 by 0.04. This compares to -$0.74 EPS in the same period last year. The company reported revenue of $46.3 million for the quarter, compared to $53.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -14.06 percent.
Gossamer Bio Inc(GOSS) Company Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
